Evidence map›Paper›PMID 37004047›Full record

ReviewMolecular cancer2023

CAR T-Cell therapy for the management of mantle cell lymphoma.

Zoufang Huang, Vivek P Chavda, Rajashri Bezbaruah, Hemant Dhamne, Dong-Hua Yang, Hong-Bing Zhao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. From lab to lifesaver: the rise of CAR T-cell therapy in oncology.Journal of the Egyptian National Cancer Institute · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Zoufang Huang *Department of Hematology, Ganzhou Key Laboratory of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Vivek P Chavda *Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, , 380009, Gujarat, India. Vivek7chavda@gmail.com.ORCID 0000-0002-7701-8597
Rajashri BezbaruahDepartment of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh, India.
Hemant DhamneProcess Development, Gene Therapy Vector Facility, Research Management and Innvotations Directorate, King's College London, London, WC2R 2LS, UK.
Dong-Hua YangNew York College of Traditional Chinese Medicine, Mineola, NY, 11501, USA.
Hong-Bing ZhaoDepartment of Oncology, the First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China. zhbzxfzzy@126.com.
Dibrugarh University · INFirst Affiliated Hospital of Gannan Medical University · CNFirst Affiliated Hospital of Xinxiang Medical University · CNKing's College London · GBNational Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad · INNew York College of Traditional Chinese Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer is still incurable. Age, male gender, rapid advancement, significant nodal involvement, elevated serum lactate dehydrogenase level, and prognostic indications including increased expression of Ki-67 and presence of TP53 mutation, are symbols of poor outcome. Advanced immunotherapy using chimeric antigen receptor (CAR)-T cells is advantageous for patients suffering from B-cell malignancies and MCL. Targeting B-cell antigens on the cell surface is a feasible approach in re-occurring (R/R) MCL because of significant responses obtained in other B-cell cancers. USFDA has approved brexucabtagene autoleucel (Tecartus, KTE-X19), a novel CAR T-cell therapy to be used in patients with MCL who have not responded to previous treatments or have relapsed. The FDA approved this new treatment depending on the outcomes of the ZUMA-2 clinical trial. Serious adverse reactions, moderate anti-tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking are major barriers to successful CAR T-cell therapy. This review is a brief synopsis of the development of CAR T-cell therapy for MCL.

Indexed as

Lymphoma, Mantle-CellLymphoma, Non-HodgkinReceptors, Chimeric AntigenAdultHumansImmunotherapy, AdoptiveMalePrognosisReceptors, Chimeric AntigenBrexucabtagene autoleucelChimeric antigen receptor T-cell therapyMantle cell lymphomaZUMA

Identifiers

PMID37004047
PMCPMC10064560
OpenAlexW4362521151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.